Acting Attorney General Todd Blanche has officially downgraded state-licensed medical marijuana to a Schedule III substance, executing a major federal policy pivot. The historic move eases research restrictions and acknowledges the drug's medical utility, though recreational use remains federally prohibited.

Acting Attorney General Todd Blanchesignedadirectiveon April23, 2026, formallytransferringstate-licensedmedicalmarijuanaandFDA-approvedcannabisproductsfrom Schedule Ito ScheduleIIIofthe Controlled Substances Act[1.7]. The maneuver executes President Donald Trump’s December 18, 2025, executive order, which mandated a rapid conclusion to the federal reclassification process. By carving out medical cannabis for immediate relief, the Department of Justice has validated the licensing systems of forty states, even as recreational marijuana remains federally banned.

This sudden regulatory shift breaks a prolonged bureaucratic logjam that had stalled the policy change for months. Previous reporting highlighted how the Drug Enforcement Administration’s administrative hearings, initially scheduled for January 2025, were indefinitely suspended by Administrative Law Judge John Mulrooney. Instead of waiting for those proceedings to resume, Blanche bypassed the bottleneck entirely. The DOJ formally terminated the old hearing docket and scheduled a new session for June 29, 2026, which will exclusively address the broader status of non-medical cannabis.

The financial and operational consequences for key stakeholders are immediate. State-sanctioned medical dispensaries and cultivators are now exempt from Section 280E of the Internal Revenue Code, permitting them to claim standard business tax deductions that were previously denied. For the scientific community, the downgrade to Schedule III dismantles decades-old barriers, allowing clinical researchers to study the drug's efficacy without navigating the severe security protocols required for Schedule I narcotics. Recreational operators, however, remain excluded from these benefits, leaving their federal standing dependent on the upcoming summer tribunal.

• ActingAGTodd Blancheofficiallymovedstate-licensedmedicalmarijuanato ScheduleIIIon April23, 2026, fulfilling Trump's December2025executiveorder[1.7].
• The DOJ bypassed stalled DEA administrative hearings, terminating the delayed January 2025 docket and setting a new June 2026 date to debate recreational cannabis.
• The reclassification grants medical cannabis operators major tax relief by removing Section 280E restrictions and significantly lowers barriers for clinical research.

**FILE UPDATE: MARKET BIFURCATION.** The immediate financial landscape has fractured into two distinct realities for the cannabis industry. By shedding the Schedule I label, state-licensed medical dispensaries are suddenly freed from Section 280E of the Internal Revenue Code [1.5]. For decades, this tax provision prevented operators from deducting standard business expenses, effectively taxing them on gross revenue. Medical operators can now claim standard corporate deductions, fundamentally altering their profit models. Yet, the recreational market is left entirely exposed. Adult-use cannabis remains federally prohibited, meaning recreational dispensaries will continue to operate without federal tax relief, bankruptcy protection, or interstate commerce rights.

**STAKEHOLDER IMPACT: RESEARCHERS.** The reclassification systematically dismantles the severe clinical study barriers that have bottlenecked scientific inquiry for half a century. Under Schedule I, universities and pharmaceutical companies faced labyrinthine Drug Enforcement Administration protocols just to handle the plant. The Schedule III downgrade streamlines the approval process for clinical trials, allowing researchers to investigate the plant's efficacy without the friction of top-tier narcotic restrictions. Biotech firms are already positioning to accelerate FDA-regulated drug pathways, signaling a rush to develop proprietary, cannabinoid-based therapies that meet federal safety standards.

**CONSEQUENCES: PATIENT ACCESS.** For patients, the most immediate shift involves federal healthcare infrastructure. The downgrade officially opens the door for Medicare and Medicaid to cover specific CBD treatments. The Centers for Medicare and Medicaid Services (CMS) is launching a pilot program allowing qualifying Medicare recipients to claim up to $500 annually in reimbursements for hemp-derived CBD products, provided they secure a physician's recommendation. While doctors still cannot write traditional prescriptions for botanical cannabis, integrating cannabinoid reimbursement into federal healthcare programs establishes a massive precedent for older adults seeking alternative pain and seizure management.

• State-licensedmedicaldispensariesgainmajortaxreliefbyescapingIRSSection280E, whiletherecreationalmarketremainsfederallyillegalandunprotected[1.5].
• The Schedule III downgrade removes severe DEA restrictions, allowing universities and biotech firms to accelerate clinical trials and FDA-regulated drug development.
• A new CMS pilot program will allow Medicare to reimburse qualifying seniors up to $500 annually for physician-recommended CBD treatments.

Since our prior reporting on the stalled January 2025 proceedings [1.16], the federal legal landscape has fractured into a bifurcated system. Acting Attorney General Todd Blanche’s April 23, 2026, directive shifts state-licensed medical cannabis to Schedule III, but it deliberately leaves recreational marijuana untouched. For anyone operating outside regulated medical frameworks, the plant remains a Schedule I narcotic under the Controlled Substances Act. This means statutory criminal penalties for unsanctioned possession and distribution are not automatically erased. Federal law enforcement agencies retain the authority to prosecute illicit market participants, creating a stark enforcement gap between protected medical patients and recreational consumers.

This partial reclassification introduces severe legal friction for stakeholders across the supply chain. Dispensaries operating in states with legalized recreational use now face a contradictory compliance environment. Their medical inventory benefits from Schedule III tax relief and research protections, while their recreational products remain federally illicit and subject to strict enforcement. Legal experts warn that this dynamic forces businesses to navigate conflicting federal and state statutes, leaving recreational consumers and non-medical operators vulnerable to federal drug enforcement policies. The Justice Department’s move legitimizes the medical sector but stops well short of the comprehensive descheduling advocates have demanded.

The ultimate resolution to this fragmented policy now hinges on a newly announced administrative hearing process set to begin on June 29, 2026. After the previous Drug Enforcement Administration hearings were indefinitely paused by an administrative law judge early last year, the Justice Department is fast-tracking proceedings to evaluate the broader reclassification of all marijuana. The stakes for these summer hearings are immense. A complete transition of all cannabis to Schedule III would harmonize federal law with the dozens of states that have already legalized the drug, fundamentally reshaping the multibillion-dollar industry and mitigating the current legal exposure for recreational operators.

• Statutory criminal penalties for unsanctioned possession and recreational use remain fully intact, as the Schedule III downgrade applies exclusively to state-licensed medical marijuana.
• Dispensaries and cannabis businesses must now navigate a bifurcated legal system, managing protected medical inventory alongside federally illicit recreational products.
• The Drug Enforcement Administration will hold expedited administrative hearings starting June 29, 2026, to determine the broader federal classification of all marijuana.

The April 23 reclassification did not happen in a vacuum; it was the direct result of a sudden Justice Department shakeup. When President Donald Trump ousted Attorney General Pam Bondi on April 2, 2026 [1.5], public attention focused on her handling of the Jeffrey Epstein files and her reluctance to prosecute perceived political adversaries. Yet, Bondi’s deep-seated opposition to marijuana reform had also effectively stalled Trump’s December 2025 executive order, which mandated a swift Schedule III downgrade. For over three months, the cannabis directive languished under her watch.

The installation of Todd Blanche as Acting Attorney General rapidly altered the agency's trajectory. As Trump’s former personal defense attorney, Blanche demonstrated an immediate willingness to execute the White House's agenda. Within weeks of taking the helm, he bypassed the bureaucratic friction that characterized Bondi's tenure, pushing through the medical cannabis reclassification and setting a firm June 29, 2026, date for new administrative hearings.

This personnel swap highlights a highly calculated political strategy. The administration is actively courting the overwhelming public consensus favoring medical cannabis access and research. However, by explicitly restricting the Schedule III designation to FDA-approved and state-licensed medical products, the White House maintains a rigid barrier against recreational legalization. This dual approach allows the administration to claim a major healthcare victory while preserving its hardline law enforcement credentials for conservative voters.

• The April2026dismissalof Pam Bondiremovedacriticalinternalroadblock, allowing Acting Attorney General Todd Blanchetofinalizethestalled December2025cannabisdirective[1.14].
• The White House's policy strictly isolates medical marijuana for federal leniency, strategically capturing moderate voters while keeping recreational cannabis federally prohibited.